A Randomised Controlled Trial of Cabergoline Prophylaxis for Ovarian Hyperstimulation Syndrome in IVF Cycles and Derivation of Biomarkers for OHSS

Trial Profile

A Randomised Controlled Trial of Cabergoline Prophylaxis for Ovarian Hyperstimulation Syndrome in IVF Cycles and Derivation of Biomarkers for OHSS

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Jun 2016

At a glance

  • Drugs Cabergoline (Primary)
  • Indications Ovarian hyperstimulation syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.
    • 03 Sep 2015 Planned End Date changed from 1 Jul 2014 to 1 Jun 2016 as reported by ClinicalTrials.gov.
    • 03 Sep 2015 Planned primary completion date changed from 1 Jul 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top